Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.63 |
| ▸ | LPL | P06858 | 12/20 | 0.63 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23750182 | 0.91 | LIPG (0.55) | LIPGLPLF11DGAT1 | |
| SCHEMBL16472961 | 0.89 | LIPG (0.54) | LIPGLPLF11DGAT1 | |
| SCHEMBL4315178 | 0.87 | LIPG (0.68) | LIPGLPLF11ROCK1ESR2 | |
| SCHEMBL29478527 | 0.87 | LIPG (0.68) | LIPGLPLF11ROCK1ESR2 | |
| SCHEMBL18332737 | 0.84 | LIPG (0.69) | LIPGLPLF11ESR2DGAT1 | |
| SCHEMBL16936864 | 0.84 | LIPG (0.74) | LIPGLPLF11ROCK1ESR2 | |
| SCHEMBL1331631 | 0.83 | LIPG (0.63) | LIPGLPLF11ENPP2 | |
| SCHEMBL3039403 | 0.83 | LIPG (0.63) | LIPGLPLF11ESR2DGAT1 | |
| SCHEMBL14120212 | 0.82 | LIPG (0.55) | LIPGLPLF11 | |
| SCHEMBL12215735 | 0.81 | LIPG (0.80) | LIPGLPLF11ESR2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025111464-A1 | JAK2 V617F INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025007113-A2 | MITOCHONDRIAL COMPLEX I INHIBITORS WITH REDUCED PHOSPHODIESTERASE INHIBITION | OHIO STATE INNOVATION FOUNDATION (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118021983-A | Preparation method and application of intelligent environmental response type treatment system for hyperuricemia and gout | 宁波慈溪生物医学工程研究所 | 2024-05-14 | — | — | CN | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007148113-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | LIPG 1712/4885LPL 1525/4885F11 4654/4885 |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | GRM1, GRM2, GRM3 | LIPG 4503/4885LPL 3856/4885F11 4521/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | LIPG 1768/4885LPL 1536/4885F11 4638/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | LIPG 1148/4885LPL 2115/4885F11 4761/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | LIPG 2295/4885LPL 2217/4885F11 2017/4885 |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | LIPG 4125/4885LPL 2909/4885F11 4770/4885 |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | PI4KA, PIK3CA, PIKFYVE | LIPG 1951/4885LPL 2653/4885F11 4497/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | LIPG 4531/4885LPL 4677/4885F11 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.